{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:15:46Z","timestamp":1772115346173,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Bisphosphonates (BPs) are widely used in clinical practice to prevent and treat bone metabolism-related diseases. Medication-related osteonecrosis of the jaw (MRONJ) is one of the major sequelae of BPs use. Early prediction and intervention of MRONJ are of great significance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Ninety-seven patients currently on treatment with BPs or with a history of BPs usage and 45 healthy volunteers undergoing dentoalveolar surgery were included in this study. Participants' serum Semaphorin 4D (Sema4D) levels were measured and analyzed before participants underwent surgery (T0) and after a 12-month follow-up (T1). Kruskal\u2013Wallis test and ROC analysis were used to examine the predictive effect of Sema4D on MRONJ.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sema4D levels in serum of patients corresponding to confirmed MRONJ were significantly lower at both T0 and T1 time points compared to non-MRONJ and healthy controls. Sema4D has a statistically predictive effect on the occurrence and diagnosis of MRONJ. Serum Sema4D levels were significantly reduced in MRONJ class 3 patients. MRONJ patients who received intravenous BPs had significantly lower Sema4D levels than those who received oral BPs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Serum Sema4D level has predictive value for the onset of MRONJ in BPs users within 12\u00a0weeks after dentoalveolar surgery.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-023-01095-6","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T07:03:26Z","timestamp":1680159806000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical values of serum Semaphorin 4D (Sema4D) in medication\u2011related osteonecrosis of the jaw"],"prefix":"10.1186","volume":"28","author":[{"given":"Hong","family":"Mu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingbo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunsheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"1095_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijsu.2019.03.004","volume":"66","author":"F Yuan","year":"2019","unstructured":"Yuan F, Peng W, Yang C, Zheng J. Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: a meta-analysis. Int J Surg. 2019;66:1\u201311.","journal-title":"Int J Surg"},{"key":"1095_CR2","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMcp1513724","volume":"374","author":"DM Black","year":"2016","unstructured":"Black DM, Rosen CJ. Clinical practice postmenopausal osteoporosis. N Engl J Med. 2016;374:254\u201362.","journal-title":"N Engl J Med"},{"key":"1095_CR3","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/jama.2020.2923","volume":"325","author":"KE Ensrud","year":"2021","unstructured":"Ensrud KE. Bisphosphonates for postmenopausal osteoporosis. JAMA. 2021;325:96.","journal-title":"JAMA"},{"key":"1095_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jsbmb.2013.09.008","volume":"142","author":"SH Tella","year":"2014","unstructured":"Tella SH, Gallagher JC. Prevention and treatment of postmenopausal osteoporosis. J Steroid Biochem Mol Biol. 2014;142:155\u201370.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"1095_CR5","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1056\/NEJMct1004903","volume":"363","author":"MJ Favus","year":"2010","unstructured":"Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med. 2010;363:2027\u201335.","journal-title":"N Engl J Med"},{"key":"1095_CR6","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41574-020-0339-7","volume":"16","author":"IR Reid","year":"2020","unstructured":"Reid IR. A broader strategy for osteoporosis interventions. Nat Rev Endocrinol. 2020;16:333\u20139.","journal-title":"Nat Rev Endocrinol"},{"key":"1095_CR7","first-page":"115","volume":"33","author":"J Kim","year":"2020","unstructured":"Kim J, Lee DH, Dziak R, Ciancio S. Bisphosphonate-related osteonecrosis of the jaw: current clinical significance and treatment strategy review. Am J Dent. 2020;33:115\u201328.","journal-title":"Am J Dent"},{"key":"1095_CR8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.23736\/S2724-6329.20.04306-X","volume":"70","author":"LH Ferreira Jr","year":"2021","unstructured":"Ferreira LH Jr, Mendonca KD Jr, de Souza JC, Dos Reis DCS, do Guedes CCFV, de Filice LSC, et al. Bisphosphonate-associated osteonecrosis of the jaw. Minerva Dent Oral Sci. 2021;70:49\u201357.","journal-title":"Minerva Dent Oral Sci"},{"key":"1095_CR9","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1097\/SAP.0000000000002650","volume":"86","author":"HI Chien","year":"2021","unstructured":"Chien HI, Chen LW, Liu WC, Lin CT, Ho YY, Tsai WH, et al. Bisphosphonate-related osteonecrosis of the jaw. Ann Plast Surg. 2021;86:S78\u201383.","journal-title":"Ann Plast Surg"},{"key":"1095_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1620\/tjem.247.75","volume":"247","author":"T Shibahara","year":"2019","unstructured":"Shibahara T. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): a twist of fate in the bone. Tohoku J Exp Med. 2019;247:75\u201386.","journal-title":"Tohoku J Exp Med"},{"key":"1095_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","volume":"69","author":"S Otto","year":"2018","unstructured":"Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiodt M. Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018;69:177\u201387.","journal-title":"Cancer Treat Rev"},{"key":"1095_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40729-021-00323-0","volume":"7","author":"M Kawahara","year":"2021","unstructured":"Kawahara M, Kuroshima S, Sawase T. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review. Int J Implant Dent. 2021;7:47.","journal-title":"Int J Implant Dent"},{"key":"1095_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-6448-2_1","volume":"1493","author":"LT Alto","year":"2017","unstructured":"Alto LT, Terman JR. Semaphorins and their Signaling Mechanisms. Methods Mol Biol. 2017;1493:1\u201325.","journal-title":"Methods Mol Biol"},{"key":"1095_CR14","doi-asserted-by":"publisher","first-page":"105044","DOI":"10.1016\/j.phrs.2020.105044","volume":"160","author":"CL Zhang","year":"2020","unstructured":"Zhang CL, Hong CD, Wang HL, Chen AQ, Zhou YF, Wan Y, et al. The role of semaphorins in small vessels of the eye and brain. Pharmacol Res. 2020;160:105044.","journal-title":"Pharmacol Res"},{"key":"1095_CR15","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1093\/bioinformatics\/btz303","volume":"35","author":"M Solmaz","year":"2019","unstructured":"Solmaz M, Lane A, Gonen B, Akmamedova O, Gunes MH, Komurov K. Graphical data mining of cancer mechanisms with SEMA. Bioinformatics. 2019;35:4413\u20138.","journal-title":"Bioinformatics"},{"key":"1095_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/cmi.2012.65","volume":"10","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Liu B, Ma Y, Jin B. Sema 4D\/CD100-plexin B is a multifunctional counter-receptor. Cell Mol Immunol. 2013;10:97\u20138.","journal-title":"Cell Mol Immunol"},{"key":"1095_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.celrep.2016.12.027","volume":"18","author":"M Hernandez-Fleming","year":"2017","unstructured":"Hernandez-Fleming M, Rohrbach EW, Bashaw GJ. Sema-1a reverse signaling promotes midline crossing in response to secreted semaphorins. Cell Rep. 2017;18:174\u201384.","journal-title":"Cell Rep"},{"key":"1095_CR18","doi-asserted-by":"publisher","first-page":"115465","DOI":"10.1016\/j.bone.2020.115465","volume":"138","author":"SH Ralston","year":"2020","unstructured":"Ralston SH. Bisphosphonates in the management of Paget\u2019s disease. Bone. 2020;138:115465.","journal-title":"Bone"},{"key":"1095_CR19","first-page":"197","volume":"27","author":"Y Takeuchi","year":"2017","unstructured":"Takeuchi Y. Innovation of bisphosphonates for improvement of adherence. Clin Calcium. 2017;27:197\u2013202.","journal-title":"Clin Calcium"},{"key":"1095_CR20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1159\/000365889","volume":"82","author":"GI Baroncelli","year":"2014","unstructured":"Baroncelli GI, Bertelloni S. The use of bisphosphonates in pediatrics. Horm Res Paediatr. 2014;82:290\u2013302.","journal-title":"Horm Res Paediatr"},{"key":"1095_CR21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bone.2011.01.014","volume":"49","author":"S Cremers","year":"2011","unstructured":"Cremers S, Papapoulos S. Pharmacology of bisphosphonates. Bone. 2011;49:42\u20139.","journal-title":"Bone"},{"key":"1095_CR22","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00198-014-3007-8","volume":"26","author":"H Molvik","year":"2015","unstructured":"Molvik H, Khan W. Bisphosphonates and their influence on fracture healing: a systematic review. Osteoporos Int. 2015;26:1251\u201360.","journal-title":"Osteoporos Int"},{"key":"1095_CR23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4103\/pm.pm_232_20","volume":"17","author":"HM Lili Liu","year":"2021","unstructured":"Lili Liu HM, Pang Ying. Caffeic acid treatment augments the cell proliferation, differentiation, and calcium mineralization in the human osteoblast-Like MG-63 cells. Pharmacogn Mag. 2021;17:6.","journal-title":"Pharmacogn Mag"},{"key":"1095_CR24","first-page":"5","volume":"17","author":"YP Hong Mu","year":"2021","unstructured":"Hong Mu YP, Liu Lili, Li F, Wang J. Citral promotes the cell proliferation, differentiation, and calcium mineralization in human osteoblast-like MG-63 Cells. Pharmacogn Mag. 2021;17:5.","journal-title":"Pharmacogn Mag"},{"key":"1095_CR25","doi-asserted-by":"publisher","first-page":"232","DOI":"10.15537\/smj.2018.3.20923","volume":"39","author":"MK AlRahabi","year":"2018","unstructured":"AlRahabi MK, Ghabbani HM. Clinical impact of bisphosphonates in root canal therapy. Saudi Med J. 2018;39:232\u20138.","journal-title":"Saudi Med J"},{"key":"1095_CR26","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1111\/j.1532-5415.2011.03713.x","volume":"59","author":"J Shannon","year":"2011","unstructured":"Shannon J, Shannon J, Modelevsky S, Grippo AA. Bisphosphonates and osteonecrosis of the jaw. J Am Geriatr Soc. 2011;59:2350\u20135.","journal-title":"J Am Geriatr Soc"},{"key":"1095_CR27","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/s41415-020-1642-3","volume":"228","author":"N Kanwar","year":"2020","unstructured":"Kanwar N, Bakr MM, Meer M, Siddiqi A. Emerging therapies with potential risks of medicine-related osteonecrosis of the jaw: a review of the literature. Br Dent J. 2020;228:886\u201392.","journal-title":"Br Dent J"},{"key":"1095_CR28","doi-asserted-by":"publisher","DOI":"10.1097\/SCS.0000000000007981","author":"S Gurav","year":"2021","unstructured":"Gurav S, Dholam KP, Singh GP. Treatment of refractory medicine related osteonecrosis of jaw with piezosurgical debridement and autologous platelet rich fibrin: feasibility study. J Craniofac Surg. 2021. https:\/\/doi.org\/10.1097\/SCS.0000000000007981.","journal-title":"J Craniofac Surg"},{"key":"1095_CR29","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10561-013-9416-7","volume":"15","author":"NM Mathijssen","year":"2014","unstructured":"Mathijssen NM, Buma P, Hannink G. Combining bisphosphonates with allograft bone for implant fixation. Cell Tissue Bank. 2014;15:329\u201336.","journal-title":"Cell Tissue Bank"},{"key":"1095_CR30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11926-004-0084-2","volume":"6","author":"SB Cohen","year":"2004","unstructured":"Cohen SB. An update on bisphosphonates. Curr Rheumatol Rep. 2004;6:59\u201365.","journal-title":"Curr Rheumatol Rep"},{"key":"1095_CR31","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/gb-2006-7-3-211","volume":"7","author":"U Yazdani","year":"2006","unstructured":"Yazdani U, Terman JR. The semaphorins. Genome Biol. 2006;7:211.","journal-title":"Genome Biol"},{"key":"1095_CR32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.conb.2020.12.014","volume":"66","author":"G Limoni","year":"2021","unstructured":"Limoni G, Niquille M. Semaphorins and Plexins in central nervous system patterning: the key to it all? Curr Opin Neurobiol. 2021;66:224\u201332.","journal-title":"Curr Opin Neurobiol"},{"key":"1095_CR33","doi-asserted-by":"publisher","first-page":"e10154","DOI":"10.15252\/emmm.201810154","volume":"12","author":"JH Wu","year":"2020","unstructured":"Wu JH, Li YN, Chen AQ, Hong CD, Zhang CL, Wang HL, et al. Inhibition of Sema4D\/PlexinB1 signaling alleviates vascular dysfunction in diabetic retinopathy. EMBO Mol Med. 2020;12:e10154.","journal-title":"EMBO Mol Med"},{"key":"1095_CR34","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1517\/14728222.2014.983078","volume":"19","author":"AD Anastasilakis","year":"2015","unstructured":"Anastasilakis AD, Polyzos SA, Makras P, Gkiomisi A, Sakellariou G, Savvidis M, et al. Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment. Expert Opin Ther Targets. 2015;19:299\u2013306.","journal-title":"Expert Opin Ther Targets"},{"key":"1095_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.bbrc.2016.10.012","volume":"480","author":"A Movila","year":"2016","unstructured":"Movila A, Mawardi H, Nishimura K, Kiyama T, Egashira K, Kim JY, et al. Possible pathogenic engagement of soluble Semaphorin 4D produced by gammadeltaT cells in medication-related osteonecrosis of the jaw (MRONJ). Biochem Biophys Res Commun. 2016;480:42\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"1095_CR36","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1177\/0022034514552676","volume":"93","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Wei L, Miron RJ, Zhang Q, Bian Z. Prevention of alveolar bone loss in an osteoporotic animal model via interference of semaphorin 4d. J Dent Res. 2014;93:1095\u2013100.","journal-title":"J Dent Res"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01095-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-023-01095-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01095-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T07:08:25Z","timestamp":1680160105000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-023-01095-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1095"],"URL":"https:\/\/doi.org\/10.1186\/s40001-023-01095-6","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"assertion":[{"value":"30 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of Cangzhou Central Hospital, and the participants signed written informed consent. The study was performed in strict accordance with the Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All participants have given consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}